Effect of mineralocorticoids on interdialytic weight gain in hemodialysis patients with perdialytic hypotension

Hemodialysis International

Volumn 9, Issue 4, 2005, Pages 338-340

  Mercadal, Lucile ^a   Petitclerc, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Fludrocortisone; Hemodialysis; Hypotension

Indexed keywords

ANGIOTENSIN; FLUDROCORTISONE; MIDODRINE; MINERALOCORTICOID; POLYSTYRENE; SODIUM;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE REPORT; DRUG MECHANISM; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; MALE; OUTCOMES RESEARCH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; THIRST; WEIGHT GAIN;

ADRENERGIC ALPHA-AGONISTS; AGED; ANTI-INFLAMMATORY AGENTS; BLOOD PRESSURE; DRUG RESISTANCE; FEMALE; FLUDROCORTISONE; HUMANS; HYPOKALEMIA; HYPOTENSION; MALE; MIDDLE AGED; MIDODRINE; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM;

EID: 27744482579     PISSN: 14927535     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2005.01150.x     Document Type: Article

References (10)

1. Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golpen TA, Agadoa LY, Young EW. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999; 33:507-517.
2. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P. U-curve association of blood pressure and mortality in hemodialysis patients. Kidney Int. 1998; 54:561-569.
3. Furuya R, Kumagai H, Sakao T, Maruyama Y, Hishida A. Potassium-lowering effect of mineralocorticoids therapy in patients undergoing hemodialysis. Nephron. 2002; 92:576-581.
4. Vlassopoulos D, Sonikian M, Dardioti V, Pani I, Hadjilouka-Mankata A, Hadjiconstantinou V. Insulin and mineralocorticoids influence on extrarenal potassium metabolism in chronic hemodialysis patients. Ren Fail. 2001; 23:833-842.
5. Singhal PC, Desroches L, Mattana J, Abramovici M, Wagner JD, Maesaka JK. Mineralocorticoid therapy lowers serum potassium in patients with end-stage renal disease. Am J Nephrol. 1993; 13:138-141.
6. Whalen JE, Cohen LH. Exogenous mineralocorticoid hormone improves predialysis hyperkaliemia in anephric man. Proc Clin Dial Transplant Forum. 1978; 8:1-4.
7. Perazella MA. Pharmacologic options available to treat symptomatic intradialytic hypotension. Am J Kidney Dis. 2001; 38(suppl 4):S26-S36.
8. Van Lieshout JJ, ten Harkel AD, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. Clin Auton Res. 2000; 10:35-42.
9. Vernikos J, Convertino VA. Advantages and disadvantages of fludrocortisone or saline load in preventing post-spaceflight orthostatic hypotension. Acta Astronaut. 1994; 33:259-266.
10. Distler A, Philipp T, Luth B, Wucherer G. Studies on the mechanism of mineralocorticoid-induced blood pressure increase in man. Clin Set (London). 1979; 57(suppl 5):303s-305s.